RE:LicensingIt is clear that Smeenk believes that he can license the ACP process to mutliple pharmas. What makes the ACP process so lucrative (besides the high efficacy rate), is that it can be used in conjuection with drug treatments to potentially address a whole array of illnesses. But it may never get this far. If the mid-term results meet expectations then purchasing HEM becomes more attractive to big pharma rather than paying a licensing fee.